NCT04120636View on ClinicalTrials.gov

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

Macula EdemaRadiation RetinopathyBranch Retinal Vein OcclusionEpiretinal MembraneCentral Serous Retinopathy With Pit of Optic DiscCommotio RetinaeVitritis

Interventions

DRUG

Episcleral Celecoxib

Sustained Release Transscleral Celecoxib

Trial Locations (1)

94303

Stanford Medicine Ophthalmology, Palo Alto

All Listed Sponsors

lead

Targeted Therapy Technologies, LLC

INDUSTRY